New shot aims to slash cholesterol in chinese heart patients
NCT ID NCT06941792
First seen Jan 07, 2026 · Last updated May 09, 2026 · Updated 13 times
Summary
This study tests whether inclisiran, a newer cholesterol-lowering drug, works better than usual care for Chinese adults with coronary heart disease. About 1,590 participants will receive either inclisiran or standard treatment, and researchers will measure how much their LDL (bad) cholesterol drops over one year. The goal is to see if inclisiran helps more patients reach their cholesterol targets and stick with treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigated Site
Taiyuan, Shanxi, 030000, China
-
Novartis Investigative Site
Anqing, Anhui, 246003, China
-
Novartis Investigative Site
Beijing, Beijing Municipality, 102218, China
-
Novartis Investigative Site
Chongqing, Chongqing Municipality, 400010, China
-
Novartis Investigative Site
Longyan, Fujian, 364099, China
-
Novartis Investigative Site
Jiamusi, Heilongjiang, 154002, China
-
Novartis Investigative Site
Zhengzhou, Henan, 451400, China
-
Novartis Investigative Site
Baotou, Inner Mongolia, 014010, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110016, China
-
Novartis Investigative Site
Shenyang, Liaoning, 121100, China
-
Novartis Investigative Site
Jining, Shandong, 272000, China
-
Novartis Investigative Site
Weifang, Shandong, 261000, China
-
Novartis Investigative Site
Shanghai, Shanghai Municipality, 200065, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610031, China
-
Novartis Investigative Site
Ürümqi, Xinjiang Uygur Autonomous Region, 830054, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310007, China
-
Novartis Investigative Site
Jinhua, Zhejiang, 321000, China
-
Novartis Investigative Site
Ningbo, Zhejiang, 315000, China
-
Novartis Investigative Site
Wenzhou, Zhejiang, 325000, China
Conditions
Explore the condition pages connected to this study.